March 2024 in “The journal of sexual medicine” The therapies improved ejaculation disorders and sexual function in middle-aged men.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
January 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Intradermal dutasteride effectively and safely improves hair growth in early-stage androgenetic alopecia.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
24 citations
,
February 1986 in “Cancer” A pancreatic tumor caused high glucagon levels and symptoms, but treatment reduced glucagon and shrank liver tumors.
Baricitinib shows promise for treating alopecia areata with mild side effects.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
12 citations
,
December 2018 in “Clinical Ophthalmology” Latanoprostene bunod effectively lowers eye pressure and is better tolerated than other glaucoma medications.
24 citations
,
November 2023 in “International Journal of Molecular Sciences” PRP and ADSC therapies show promise in improving symptoms of genital lichen sclerosus with minimal side effects.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
30 citations
,
February 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.
3 citations
,
May 2016 in “Gynecological Endocrinology” Low-dose flutamide improved hirsutism and satisfaction in women but had common side effects, causing some to stop treatment.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
1 citations
,
September 2023 in “JCEM case reports” GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
7 citations
,
August 1985 in “British journal of dermatology/British journal of dermatology, Supplement” Medroxyprogesterone acetate injections are more effective than topical ointment in treating excessive hair growth in women.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
16 citations
,
December 2001 in “The Journal of Dermatology” A woman recovered from hair loss and skin eruptions after stopping a tuberculosis drug and using steroids.
May 2008 in “10th European Congress of Endocrinology” December 2017 in “The Sri Lanka Journal of Dermatology” Infliximab successfully treated a severe hair loss case in Sri Lanka.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
January 2012 in “Nei Mongol Journal of Traditional Chinese Medicine” Zusanli acupoint injection of metoclopramide effectively treats functional dyspepsia.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
5 citations
,
August 2018 in “Neurology and Therapy” Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.